Forum Topic News
  • Conversation: Roche's lung cancer combination treatment improves long-term survival

    • December 14, 2021 11:48 AM GMT
      • Post(s)

      Roche's lung cancer combination treatment improves long-term survival

      Almost a year ago, Roche’s immune checkpoint inhibitor tiragolumab became the first anti-TIGIT therapy to gain breakthrough designation by the US Food and Drug Administration (FDA) after more than a decade of research.
      The FDA decision was based on data from the phase 2 CITYSCAPE study that is evaluating tiragolumab plus Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) compared with Tecentriq alone in first-line PD-L1-positive, locally advanced unresectable or metastatic non-small cell lung cancer.
      In January 2021, the data suggested that the combination showed an improvement in overall response rate (ORR) of 37% vs 21% with Tecentriq alone and a 42% reduction in progression-free survival (PFS) over Tecentriq alone after an average of 10.9 months follow-up.
      People with high levels of PD-L1 saw a 66% ORR (versus 24% for Tecentriq alone).
      Now, Roche has announced longer-term data from the trial that shows ‘encouraging results’ at 2.5 years median follow-up. The intention-to-treat population (ITT) – all randomised study participants – continued to show an improvement. After 2.5 years, tiragolumab and Tecentriq reduced progression-free survival by 38% and improved ORR (38.8% vs 20.6%) compared with Tecentriq alone.
      However, this improvement was driven by strong performance in the high PD-L1 population, which showed a 71% reduction in the risk of disease worsening or death and a clinically meaningful improvement in ORR (69% vs 24.1%) compared with Tecentriq alone.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel